Milestone Pharmaceuticals Inc (MIST) reports FDA approval and successful launch of CARDAMYST, while navigating insurance hurdles and financial losses.

Milestone Pharmaceuticals Inc. MIST shares are tumbling on Friday after the company revealed a minor pushback in European approval for its lead drug. • Milestone Pharmaceuticals stock is taking a hit ...

Milestone Pharmaceuticals (NASDAQ:MIST) executives highlighted the company’s transition to commercialization during a ...

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in ...

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated ...

MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced Monday that its recently approved CARDAMYST (etripamil) nasal spray is now available through U.S. retail pharmacies for ...

Credit: Milestone Pharmaceuticals. Each nasal spray device delivers 2 sprays containing a total of etripamil 70mg. The intranasal therapy consists of a novel calcium channel blocker and is designed to ...

MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced Tuesday that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application for etripamil nasal ...

If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting MONTREAL and CHARLOTTE, N.C., Jan.

Milestone Pharmaceuticals ( (MIST)) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European Medicines Agency has accepted its Marketing Authorization ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) ...